NEW YORK (GenomeWeb News) — Ferrer in Code will distribute Agendia’s MammaPrint breast cancer recurrence assay and its CupPrint cancer of unknown primary test in Spain, Agendia said today.
 
Agendia CEO Bernhard Sixt said the partners are currently discussing “future steps in order to intensify the co-operation in other parts of the world.”
 
Ferrer in Code is a subsidiary of the pharmaceutical company Ferrer.
 
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.